Market Cap : 5.61 B | Enterprise Value : 7.17 B | PE Ratio : At Loss | PB Ratio : 1.07 |
---|
NYSE:PRGO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:PRGO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROE % is calculated as Net Income attributable to Common Stockholders (Net Income minus dividends to participating security holders) divided by its average Total Stockholders Equity over a certain period of time. Perrigo Co's annualized net income attributable to common stockholders for the quarter that ended in Mar. 2022 was $-10 Mil. Perrigo Co's average Total Stockholders Equity over the quarter that ended in Mar. 2022 was $5,128 Mil. Therefore, Perrigo Co's annualized ROE % for the quarter that ended in Mar. 2022 was -0.19%.
The historical rank and industry rank for Perrigo Co's ROE % or its related term are showing as below:
During the past 13 years, Perrigo Co's highest ROE % was 23.76%. The lowest was -48.18%. And the median was 2.09%.
PRGO's ROE % is ranked worse thanThe historical data trend for Perrigo Co's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's ROE % distribution charts can be found below:
* The bar in red indicates where Perrigo Co's ROE % falls into.
Perrigo Co's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as
ROE % | = | Net Income attributable to Common Stockholders (A: Dec. 2021 ) | / | ( (Total Stockholders Equity (A: Dec. 2020 ) | + | Total Stockholders Equity (A: Dec. 2021 )) | / count ) |
= | -68.9 | / | ( (5655.1 | + | 5151.7) | / 2 ) | |
= | -68.9 | / | 5403.4 | ||||
= | -1.28 % |
Perrigo Co's annualized ROE % for the quarter that ended in Mar. 2022 is calculated as
ROE % | = | Net Income attributable to Common Stockholders (Q: Mar. 2022 ) | / | ( (Total Stockholders Equity (Q: Dec. 2021 ) | + | Total Stockholders Equity (Q: Mar. 2022 )) | / count ) |
= | -9.6 | / | ( (5151.7 | + | 5104.5) | / 2 ) | |
= | -9.6 | / | 5128.1 | ||||
= | -0.19 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income attributable to common stockholders of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is four times the quarterly (Mar. 2022) net income attributable to common stockholders data. ROE % is displayed in the 30-year financial page.
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
ROE %** | (Q: Mar. 2022 ) | ||||
= | Net Income | / | Total Stockholders Equity | ||
= | -9.6 | / | 5128.1 | ||
= | (Net Income / Revenue ) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (-9.6 / 4298) | * | (4298 / 10407.6) | * | (10407.6 / 5128.1) |
= | Net Margin % | * | Asset Turnover | * | Equity Multiplier |
= | -0.22 % | * | 0.413 | * | 2.0295 |
= | ROA % | * | Equity Multiplier | ||
= | -0.09 % | * | 2.0295 | ||
= | -0.19 % |
With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.
The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:
ROE %** | (Q: Mar. 2022 ) | ||||||||
= | Net Income | / | Total Stockholders Equity | ||||||
= | -9.6 | / | 5128.1 | ||||||
= | (Net Income /Pre-Tax Income) | * | (Pre-Tax Income/Operating Income) | * | (Operating Income/Revenue) | * | (Revenue/Total Assets) | * | (Total Assets/Total Stockholders Equity) |
= | (-9.6 / -52) | * | (-52 / 101.2) | * | (101.2 / 4298) | * | (4298 / 10407.6) | * | (10407.6 / 5128.1) |
= | Tax Burden | * | Interest Burden | * | Operating Margin % | * | Asset Turnover | * | Equity Multiplier |
= | 0.1846 | * | -0.5138 | * | 2.35 % | * | 0.413 | * | 2.0295 |
= | -0.19 % |
Note: The net income attributable to common stockholders data used here is four times the quarterly (Mar. 2022) net income attributable to common stockholders data. The Revenue data used here is four times the quarterly (Mar. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
Net income attributable to common stockholders is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Thank you for viewing the detailed overview of Perrigo Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Ives Alison | officer: EVP & Chief Scientific Officer | C/O PERRIGO COMPANY PLC 515 EASTERN AVENUE ALLEGAN MI 49010 |
Hanson Kyle | officer: EVP & General Counsel | |
Bezerra Eduardo Guarita | officer: EVP & Chief Financial Officer | C/O FRESH DEL MONTE PRODUCE INC. PO BOX 149222 CORAL GABLES FL 33134 |
Ashford Orlando D | director | C/O AMERANT BANK 220 ALHAMBRA CR. CORAL GABLES FL 33134 |
Doyle Katherine C. | director | 100 ABBOTT PARK ROAD, AP6C-1N D032L ABBOTT PARK IL 60064 |
Sorota Richard S | officer: EVP & President CSCA | HARMAN INTERNATIONAL INDUSTRIES, INC. 1101 PENNSYLVANIA AVE, NW, #1010 WASHINGTON DC 20004 |
Mann Erica L | director | ONE KELLOGG SQUARE P.O. BOX 3599 BATTLE CREEK MI 49016-3599 |
Silcock Raymond | officer: EVP, Chief Financial Officer | 399 JEFFERSON ROAD PARSIPPANY NJ 07054 |
Willis Robert | officer: Acting CHRO | C/O PERRIGO COMPANY PLC 515 EASTERN AVENUE ALLEGAN MI 49010 |
Dillard James E Iii | officer: EVP, Chief Scientific Officer | 6601 WEST BROAD STREET RICHMOND VA 23230 |
Kessler Murray S | director, officer: CEO | 714 GREEN VALLEY ROAD GREENSBORO NC 27408 |
Smith Jeffrey C | director | 777 THIRD AVENUE, 18TH FLOOR NEW YORK NY 10017 |
Roehrhoff Uwe | director, officer: CEO | C/O PERRIGO COMPANY PLC TREASURY BUILDING, LOWER GRAND CANAL ST DUBLIN L2 D2 |
Classon Rolf A | director | C/O CATALENT, INC. 14 SCHOOLHOUSE ROAD SOMERSET NJ 08873 |
Karaboutis Adriana | director | C/O BIOGEN IDEC INC. 225 BINNEY ST. CAMBRIDGE MA 02142 |
From GuruFocus
By PRNewswire 02-16-2022
By PRNewswire 08-03-2021
Other Sources
By Zacks 2022-02-22
By Zacks 2021-11-15
By Zacks 2021-11-08
By Zacks 2021-12-07
By Zacks 2022-03-29
By Zacks 2022-02-15
By Zacks 2021-11-10
By Seekingalpha 2022-03-01
By Zacks 2022-02-15
By Zacks 2022-02-10
By Zacks 2022-01-27
By Seekingalpha 2021-11-10
By Zacks 2022-02-08